Fulcrum Therapeutics
Clinical trials sponsored by Fulcrum Therapeutics, explained in plain language.
-
Hope for FSHD: experimental drug losmapimod moves to safety testing
Disease control TerminatedThis study tested a drug called losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD), a rare disease that causes muscle weakness. The main goal was to see if long-term use of the drug is safe and tolerable. Participants were adults aged 18 to 65 who had already…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 17, 2026 02:21 UTC
-
New drug shows promise for rare muscle disease in early trial
Disease control TerminatedThis study tested a drug called losmapimod in 14 adults with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a rare genetic condition that causes muscle weakness. The main goal was to check if the drug is safe and tolerable, and to see how it affects certain markers in the…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Hope for FSHD: experimental drug losmapimod tested in major trial
Disease control TerminatedThis study tested a drug called losmapimod in 260 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. Participants took either the drug or a placebo for 48 weeks to see if it could slow muscle decline. The trial was terminat…
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:41 UTC